Canadian Life Companies Split Renews ATM Equity Program

Canadian Life Companies Split (LFE.TO) has renewed its at-the-market equity (ATM) program, the company said on Wednesday.

The program is effective until July 2, 2028, and replaces the prior program established in October 2025 that has terminated.

The maximum proceeds from the shares issued under the program will be $140 million, which will be used primarily for investment.

Canadian Life invests in an actively managed portfolio of companies which primarily includes Great-West Lifeco (GWO.TO), Industrial Alliance Insurance & Financial Services (IAG.TO), Manulife Financial (MFC.TO) and Sun Life Financial (SLF.TO).

Canadian Life shares were last seen up $0.04, to $7.75, on the Toronto Stock Exchange.

Price: $7.74, Change: $+0.03, Percent Change: +0.39%

Metallic Minerals Upsizes Bought Deal LIFE Private Placement to Gross Proceeds of C$10 Million; Shares up 4%

Metallic Minerals (MMG.V) increased the gross proceeds of its previously announced "bought deal" private placement to around C$10 million from around C$8 million, the company said on Wednesday.The company has entered into an amended agreement with Red Cloud Securities Inc, as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters.The underwriters have agreed to purchase for resale, with the right to arrange for substitute purchasers to purchase, around 17.86 million units of the company at a price of C$0.28 each for gross proceeds of around C$5 million from the sale of units, and around 12.99 million flow-through units of the company at a price of C$0.385 each for gross proceeds of around C$5 million from the sale of charity FT units.Each unit will consist of one common share and one-half of one common share purchase warrant. Each charity FT unit will consist of one common share and one-half of one common share purchase warrant."Each Charity FT Unit Share and each half of one Charity FT Unit Warrant comprising a Charity FT Unit will qualify as a "flow-through share" within the meaning of subsection 66(15) of the Income Tax Act (Canada)," said the company.Each whole unit warrant and charity FT unit warrant shall entitle the holder to purchase one common share of the company on a non-flow-through basis at a price of C$0.40 at any time during the period beginning on the date that is 61 days following the closing date and ending on the date which is 36 months following the closing date.The company will grant to the underwriters an option, exercisable in full or in part, up to 48 hours prior to the closing date, to purchase for resale up to that number of additional offered securities in any combination of units and charity FT units at their respective offering prices for additional gross proceeds of up to C$2 million.The company plans to use the net proceeds from the sale of units for the exploration and advancement of its La Plata Project in southwestern Colorado, as well as for general corporate purposes and working capital.The gross proceeds from the sale of charity FT units will be used by the company to incur eligible "Canadian exploration expenses" that qualify as "flow-through mining expenditures" as such terms are defined in the Income Tax Act related to the company's Keno Silver Project in the Yukon Territory on or before Dec. 31, 2027.The offering is scheduled to close on June 22, 2026 or such other date as the company and Red Cloud may agree, said the company and added that the completion of the offering is subject to certain conditions.The company's shares were last seen up $0.01 at $0.26 on the TSX Venture Exchange.Price: $0.26, Change: $+0.01, Percent Change: +4.00%

$MMG.V

Medicenna Therapeutics Provides MDNA11 Update

Medicenna Therapeutics (MDNA.TO) said Wednesday that its lead compound MDNA11 was featured in a poster presentation describing the investigator-sponsored NEO-CYT trial at the American Society of Clinical Oncology (ASCO), annual meeting in Chicago.While surgery has been the first course of action in treating locally advanced melanoma, a recent study has shown that administering combination immunotherapy, comprised of two pre-operative cycles of ipilimumab plus nivolumab, is much more effective than the previous post-surgery standard.However, 41% of patients did not achieve a major pathologic response (meaning "NEO-CYT provides an important opportunity to evaluate MDNA11, a potentially best-in-class IL-2 superagonist, in a frontline neoadjuvant setting where immune activation may be especially impactful," said Fahar Merchant, chief executive officer. " If the tumor is still present at the time of the treatment, the immune cells 'see' more of the cancer cells. This allows the most potent anti-tumor immune cells to expand and attack the tumor and can remain active in the body for many years, preventing the tumors from recurring."Merchant noted that the NEO-CYT trial complements Medicenna's ongoing ABILITY-1 study, which is also advancing MDNA11 into earlier lines of therapy through expansion cohorts in various cancers.The company will share updates on the ABILITY-1 trial and the NEO-CYT study in the second half of this year.Medicenna shares were last seen up $0.005, to $0.425, on the Toronto Stock Exchange.Price: $0.43, Change: $+0.01, Percent Change: +1.19%

$MDNA.TO

Canadian Life Companies Split Renews ATM Equity Program

Related Articles

Metallic Minerals Upsizes Bought Deal LIFE Private Placement to Gross Proceeds of C$10 Million; Shares up 4%

Medicenna Therapeutics Provides MDNA11 Update

RBC Precious Metals Price Target Changes Brief: Kinross To US$40 From $45; FNV To US$295 From $320; TFPM To US$38 From $44; OR To US$50 From $56; WPM To US$165 From $200